The association between osteopontin and survival in non-small-cell lung cancer patients: A meta-analysis of 13 cohorts

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 3513-3521

  Wang, Ying ^a   Yang, Jin ^a   Liu, Hui ^a   Bi, Ji Rui ^a   Liu, Ying ^a   Chen, Yan Yan ^a   Cao, Ji Yu ^a   Lu, You Jin ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Disease free survival; Metastasis; Overall survival; Tumor stage

Indexed keywords

OSTEOPONTIN;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; HIGH RISK PATIENT; HUMAN; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENCE FREE SURVIVAL; SURVIVAL PREDICTION;

EID: 84948977042     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S94082     Document Type: Article

References (35)

1. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111(6):1710-1717.
2. Ishikawa M, Miyahara R, Sonobe M, et al. Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma. Lung Cancer. 2012; 76(3):431-438.
3. Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001; 107(9):1055-1061.
4. Chuang CY, Chang H, Lin P, et al. Up-regulation of osteopontin expression by aryl hydrocarbon receptor via both ligand-dependent and ligand-independent pathways in lung cancer. Gene. 2012;492(1):262-269.
5. Zhao B, Sun T, Meng F, et al. Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer. J Cancer Res Clin Oncol. 2011;137(7):1061-1070.
6. Boldrini L, Donati V, Dell’Omodarme M, et al. Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer. 2005;93(4):453-457.
7. Donati V, Boldrini L, Dell’Omodarme M, et al. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res. 2005;11(18):6459-6465.
8. Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer. 2010;103(6):861-869.
9. Hu Z, Lin D, Yuan J, et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res. 2005;11(13):4646-4652.
10. Schneider S, Yochim J, Brabender J, et al. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res. 2004;10(5): 1588-1596.
11. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Kim SK. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer. 2007;57(3):373-380.
12. Isa S, Kawaguchi T, Teramukai S, et al. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J Thorac Oncol. 2009;4(9): 1104-1110.
13. Takenaka M, Hanagiri T, Shinohara S, et al. Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer. Clin Lung Cancer. 2013;14(3):288-294.
14. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa (ON): Ottawa Health Research Institute. Available from: www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed November 10, 2015.
15. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21(11):1559-1573.
16. Song F, Gilbody S. Bias in meta-analysis detected by a simple, graphical test. Increase in studies of publication bias coincided with increasing use of meta-analysis. BMJ. 1998;316(7129):471.
17. Sun BS, Li Y, Zhang ZF, You J, Wang CL. Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. Ann Thorac Surg. 2013;96(6): 1943-1951.
18. Chambers AF, Wilson SM, Kerkvliet N, O’Malley FP, Harris JF, Casson AG. Osteopontin expression in lung cancer. Lung Cancer. 1996; 15(3):311-323.
19. Rud AK, Boye K, Oijordsbakken M, et al. Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer. 2013;13:540.
20. Zhang L, Hou X, Lu S, et al. Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study. Lung Cancer. 2010;67(1):114-119.
21. Mack PC, Redman MW, Chansky K, et al; SWOG. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol. 2008;26(29):4771-4776.
22. Zhang T, Zhang DM, Zhao D, Hou XM, Yang TN. Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer. J BUON. 2014;19(3):742-748.
23. Han SS, Lee SJ, Kim WJ, et al. Plasma osteopontin is a useful diagnostic biomarker for advanced non-small cell lung cancer. Tuberc Respir Dis (Seoul). 2013;75(3):104-110.
24. Ostheimer C, Bache M, Guttler A, Kotzsch M, Vordermark D. A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor. Strahlenther Onkol. 2014;190(3): 276-282.
25. Yan CH, Lv M, Li H, et al. Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection. J Cancer Res Clin Oncol. 2015;141(8):1371-1378.
26. E Y, He N, Wang Y, Fan H. Percutaneous transluminal angioplasty (PTA) alone versus PTA with balloon-expandable stent placement for short-segment femoropopliteal artery disease: a metaanalysis of randomized trials. J Vasc Interv Radiol. 2008;19(4):499-503.
27. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA. 2002;287(13):1671-1679.
28. Ue T, Yokozaki H, Kitadai Y, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer. 1998;79(2):127-132.
29. Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med. 2001;1(5):621-632.
30. Yu TT, Han ZG, Shan L, et al. Expression of osteopontin in non-small cell lung cancer and correlative relation with microvascular density. Asian Pac J Cancer Prev. 2014;15(1):29-32.
31. Le QT, Chen E, Salim A, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 2006;12(5):1507-1514.
32. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res. 2001;7(12):4060-4066.
33. Karapanagiotou EM, Terpos E, Dilana KD, et al. Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients. Med Oncol. 2010;27(2):332-338.
34. Ostheimer C, Bache M, Güttler A, Reese T, Vordermark D. Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer. BMC Cancer. 2014;14:858.
35. Trikalinos TA, Salanti G, Zintzaras E, Ioannidis JP. Meta-analysis methods. Adv Genet. 2008;60:311-334.